Recent Advances in Hepatitis B Treatment

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Jun 2

PMID 34062711

Citations 19

Authors

Georgia-Myrto Prifti

Dimitrios Moianos

Erofili Giannakopoulou

Vasiliki Pardali

John E Tavis

Grigoris Zoidis

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells. Thus, achieving a "functional cure" of the infection remains a real challenge. Recent findings concerning the viral replication cycle have led to development of novel therapeutic approaches including viral entry inhibitors, epigenetic control of cccDNA, immune modulators, RNA interference techniques, ribonuclease H inhibitors, and capsid assembly modulators. Promising preclinical results have been obtained, and the leading molecules under development have entered clinical evaluation. This review summarizes the key steps of the HBV life cycle, examines the currently approved anti-HBV drugs, and analyzes novel HBV treatment regimens.

Citing Articles

Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.

Nguyen L, Nguyen T, Kim J, Jeong J J Nanobiotechnology. 2024; 22(1):745.

PMID: 39616384 PMC: 11608496. DOI: 10.1186/s12951-024-03004-3.

Novel Pyrazino[1,2-]indole-1,3(2,4)-dione Derivatives Targeting the Replication of Viruses: Structural and Mechanistic Insights.

Giannakopoulou E, Akrani I, Mpekoulis G, Frakolaki E, Dimitriou M, Myrianthopoulos V Viruses. 2024; 16(8).

PMID: 39205212 PMC: 11360281. DOI: 10.3390/v16081238.

-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H.

Moianos D, Makri M, Prifti G, Chiotellis A, Pappas A, Woodson M Molecules. 2024; 29(12).

PMID: 38931006 PMC: 11206691. DOI: 10.3390/molecules29122942.

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.

Yuen M, Chuang W, Peng C, Jeng W, Su W, Chang T Clin Mol Hepatol. 2024; 30(3):375-387.

PMID: 38528825 PMC: 11261219. DOI: 10.3350/cmh.2023.0535.

Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibition.

Giannakopoulou E, Pardali V, Edwards T, Woodson M, Tajwar R, Tavis J Antiviral Res. 2024; 223:105833.

PMID: 38325606 PMC: 11533872. DOI: 10.1016/j.antiviral.2024.105833.

References

Gish R, Yuen M, Chan H, Given B, Lai C, Locarnini S . Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res. 2015; 121:97-108. DOI: 10.1016/j.antiviral.2015.06.019. View

Edwards T, Mani N, Dorsey B, Kakarla R, Rijnbrand R, Sofia M . Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors. Antiviral Res. 2019; 164:70-80. PMC: 10587990. DOI: 10.1016/j.antiviral.2019.02.005. View

McGowan D, Herschke F, Pauwels F, Stoops B, Last S, Pieters S . Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus. J Med Chem. 2016; 59(17):7936-49. DOI: 10.1021/acs.jmedchem.6b00747. View

Trepo C . A brief history of hepatitis milestones. Liver Int. 2013; 34 Suppl 1:29-37. DOI: 10.1111/liv.12409. View

Datta S, Chatterjee S, Veer V, Chakravarty R . Molecular biology of the hepatitis B virus for clinicians. J Clin Exp Hepatol. 2015; 2(4):353-65. PMC: 3940099. DOI: 10.1016/j.jceh.2012.10.003. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Ye X, Zhou M, He Y, Wan Y, Bai W, Tao S . Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide. Sci Rep. 2016; 6:29391. PMC: 4935942. DOI: 10.1038/srep29391. View

Salimzadeh L, Bert N, Dutertre C, Gill U, Newell E, Frey C . PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018; 128(10):4573-4587. PMC: 6159957. DOI: 10.1172/JCI121957. View

Kang C, Syed Y . Bulevirtide: First Approval. Drugs. 2020; 80(15):1601-1605. DOI: 10.1007/s40265-020-01400-1. View

10.

Clark D, Hu J . Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development. Antiviral Res. 2015; 123:132-7. PMC: 4639421. DOI: 10.1016/j.antiviral.2015.09.011. View

11.

Buhlig T, Bowersox A, Braun D, Owsley D, James K, Aranda A . Molecular, Evolutionary, and Structural Analysis of the Terminal Protein Domain of Hepatitis B Virus Polymerase, a Potential Drug Target. Viruses. 2020; 12(5). PMC: 7291194. DOI: 10.3390/v12050570. View

12.

Du K, Liu J, Broering R, Zhang X, Yang D, Dittmer U . Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections. Expert Opin Drug Discov. 2018; 13(7):661-670. DOI: 10.1080/17460441.2018.1473372. View

13.

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T . First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016; 65(3):483-9. DOI: 10.1016/j.jhep.2016.04.013. View

14.

Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F . A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol. 2015; 89(23):11945-53. PMC: 4645323. DOI: 10.1128/JVI.01855-15. View

15.

Rijckborst V, Sonneveld M, Janssen H . Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?. Aliment Pharmacol Ther. 2011; 33(5):501-13. DOI: 10.1111/j.1365-2036.2010.04555.x. View

16.

Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R . De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. Cell Chem Biol. 2018; 25(7):906-915.e5. DOI: 10.1016/j.chembiol.2018.04.011. View

17.

Xia Y, Guo H . Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020; 180:104824. PMC: 7387223. DOI: 10.1016/j.antiviral.2020.104824. View

18.

Nowotny M, Yang W . Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release. EMBO J. 2006; 25(9):1924-33. PMC: 1456928. DOI: 10.1038/sj.emboj.7601076. View

19.

Hu J, Liu K . Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017; 9(3). PMC: 5371811. DOI: 10.3390/v9030056. View

20.

Hu Y, Cheng X, Cao F, Huang A, Tavis J . β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res. 2013; 99(3):221-9. DOI: 10.1016/j.antiviral.2013.06.007. View